Next Article in Journal
Innovative Therapies Targeting the Virus and the Host for Treating Chronic Hepatitis B Virus Infection: From Bench to Bedside
Previous Article in Journal
Adverse Events and Safety Profile of the COVID-19 Vaccines in Adolescents: Safety Monitoring for Adverse Events Using Real-World Data
Previous Article in Special Issue
Assessment of Seroconversion after SARS-CoV-2 Vaccination in Patients with Lung Cancer
Brief Report

Significant Increase in Blood Pressure Following BNT162b2 mRNA COVID-19 Vaccination among Healthcare Workers: A Rare Event

1
Third Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Sotiria Hospital, 11527 Athens, Greece
2
Department of Allergy, Sotiria Hospital, 11527 Athens, Greece
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: S. Louise Cosby
Vaccines 2022, 10(5), 745; https://doi.org/10.3390/vaccines10050745
Received: 25 April 2022 / Accepted: 5 May 2022 / Published: 10 May 2022
(This article belongs to the Special Issue Oncology in the Era of SARS-CoV-2)
This brief report examined the frequency and characteristics of a significant blood-pressure (BP) increase after Pfizer-BioNTech BNT162b2 vaccination among healthcare workers who were advised to measure their BP at home. A total of 797 participants (mean age 48.1 ± 10.8 years, 63% women, 39% smokers) were included in the analysis. Seven participants reported an increase in their BP (three in the range of grade 2 and four in the range of grade 3 hypertension). Only one participant had a history of treated hypertension. The BP increase was observed at the end of the first week after the first dose, lasted for 3 to 4 days, and recurred promptly after the second dose. Only one case required hospitalization, mainly due to a history of cardiovascular disease (follow-up). Individuals experiencing a BP increase compared with those not reporting issues with their BP had a higher mean age and similar distribution of sex and non-smoking status. In conclusion, a significant BP increase after Pfizer-BioNTech vaccination seems to be rare and of a benign and transient nature. Monitoring the BP before and after vaccination might be advisable only for selected individuals with a high cardiovascular risk. View Full-Text
Keywords: BNT162b2 vaccine; COVID-19; blood pressure; hypertension BNT162b2 vaccine; COVID-19; blood pressure; hypertension
Show Figures

Figure 1

MDPI and ACS Style

Syrigos, N.; Kollias, A.; Grapsa, D.; Fyta, E.; Kyriakoulis, K.G.; Vathiotis, I.; Kotteas, E.; Syrigou, E. Significant Increase in Blood Pressure Following BNT162b2 mRNA COVID-19 Vaccination among Healthcare Workers: A Rare Event. Vaccines 2022, 10, 745. https://doi.org/10.3390/vaccines10050745

AMA Style

Syrigos N, Kollias A, Grapsa D, Fyta E, Kyriakoulis KG, Vathiotis I, Kotteas E, Syrigou E. Significant Increase in Blood Pressure Following BNT162b2 mRNA COVID-19 Vaccination among Healthcare Workers: A Rare Event. Vaccines. 2022; 10(5):745. https://doi.org/10.3390/vaccines10050745

Chicago/Turabian Style

Syrigos, Nikolaos, Anastasios Kollias, Dimitra Grapsa, Eleni Fyta, Konstantinos G. Kyriakoulis, Ioannis Vathiotis, Elias Kotteas, and Ekaterini Syrigou. 2022. "Significant Increase in Blood Pressure Following BNT162b2 mRNA COVID-19 Vaccination among Healthcare Workers: A Rare Event" Vaccines 10, no. 5: 745. https://doi.org/10.3390/vaccines10050745

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop